Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT942524DMRDPPTRCTA: DoD Psychedelic Treatment Research Clinical Trial Award

Closed Closed October 4, 2024 Opportunity HT942524DMRDPPTRCTA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2024.

• Total funding$9.8 million
• Expected awards2
• Cost sharingNot required
• Funding typeGrant

Key dates

Who can apply

This opportunity was open to colleges and universities and state and local governments.

• State governments
• Public and State controlled institutions of higher education
• Private institutions of higher education
• Others (see text field entitled "Additional Information on Eligibility" for clarification)

-A department or agency of the federal government or a state government -An academic institution -A research foundation partnering with a federal government organization -Federal government organizations

More grants for colleges and universities, state and local governments.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The intent of the DMRDP PTRCTA is to support clinical trials with eligible U.S. Service Members to evaluate treatments for post-traumatic stress disorder (PTSD) and/or traumatic brain injury (TBI) involving the use of covered psychedelic substances. Applicants must select at least one of the two covered conditions (PTSD, TBI, or both) and one or more of the covered psychedelic substances listed below. Treatment may involve the use of covered psychedelic substances alone or in conjunction with other evidence-based treatments. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. Covered psychedelic substances include: • 3,4-Methylenedioxy-methamphetamine (commonly known as “MDMA”) • psilocybin • ibogaine • 5-Methoxy-N,N-dimethyltryptamine (commonly known as “5-MeO-DMT”) • plant-based alternative therapies Per Section 723 of the National Defense Authorization Act for Fiscal Year 2024, the “Secretary of Defense may authorize any member of the Armed Forces serving on active duty who is diagnosed with a covered condition (PTSD or TBI) to participate in a clinical trial that is conducted using funding awarded under this section and is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), without regard to— (1) whether the clinical trial involves a substance included in the schedule under section 202 of the Controlled Substances Act (21 U.S.C. 812); or (2) section 912a of title 10, United States Code (article 112a of the Uniform Code of Military Justice).” Military Relevance and Military Service Collaboration: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.